Centre for Human Drug Research, Netherlands

The Centre for Human Drug Research (CHDR) in Leiden, Netherlands is a world-class early-phase clinical research organization conducting approximately 60 trials per year, with a specialist psychiatry department that has become one of Europe’s leading sites for psychedelic compound research—including psilocybin, DMT, MDMA, and ketamine—using advanced tools such as the NeuroCart CNS battery and EEG to quantify pharmacodynamic endpoints. CHDR has conducted first-in-human studies with novel non-hallucinogenic neuroplastogens and intravenous DMT regimens, establishing it as a key early-phase partner for psychedelic drug development.